2026 CRBE Summit East - Innovations in Controlled Release, Bioavailability Enhan

As pharmaceutical pipelines increasingly yield complex APIs—including poorly permeable small molecules and peptides—first-generation drug products often fall short of the ideal Target Product Profile. Sub-optimal bioavailability, positive food effects, and reliance on parenteral administration present significant hurdles to patient compliance and market success.
This presentation explores how lipid-based formulations provide a proven, low-risk toolkit for strategic lifecycle management and 505(b)(2) reformulations. By leveraging IID-listed lipid excipients, formulators can mitigate absorption challenges for small molecules, develop specialized dosage forms, and even achieve the “holy grail” of patient-centricity—oral peptide delivery.
Highlighting real-world case studies and future-facing formulation approaches, this session will demonstrate how lipid excipients enable value-added reformulations that bring new life to existing assets.